Arca
Skip to content

Transfusion dependent thalassemia

Drug research and approvals for transfusion dependent thalassemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 26 studies of transfusion dependent thalassemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 26
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 26 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Apr 6, 2022A multicenter study to evaluate the safety, tolerability, and efficacy of a single dose of autologous clustered regularly interspaced short palindromic repeats…EDIT-301 / MOZOBIL / FILGRASTIMEDITAS MEDICINE, INC.Ongoing
Oct 28, 2021A phase 3 study to evaluate the safety and efficacy of a single dose of ctx001 in pediatric subjects with transfusion-dependent ¿-thalassemiaEXAGAMGLOGENE AUTOTEMCEL (CTX001) / BUSULFAN / PLERIXAFORVertex PharmaceuticalsOngoing
Jul 12, 2018A phase 1/2 study of the safety and efficacy of a single dose of autologous crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells (hhspcs)…CTX001/ BUSULFAN / PLERIXAFORCRISPR THERAPEUTICS INCOngoing
Dec 5, 2014Multicenter, open-label, dose-escalation study of sp 420 in subjects with transfusion-dependent thalassemiaSP-420SIDERIS PHARMACEUTICALS INCOngoing
Jul 3, 2014The use of the calcium channel blocker amlodipine as an adjuvant treatment to iron chelation for the prevention of iron overload cardiomyopathy in patients…AMLODIPINEUNIVERSITY HEALTH NETWORKOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Jan 23, 2013Exjade; Jadenu SprinklesTreatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and…Novartis Pharmaceuticals CorporationApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.